Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

L-DOS 47

Drug Profile

L-DOS 47

Alternative Names: L-DOS47

Latest Information Update: 13 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Helix BioPharma
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Ureases
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Lung cancer; Non-small cell lung cancer
  • Preclinical Pancreatic cancer

Most Recent Events

  • 07 Aug 2019 USFDA approves an IND application for a phase I/II trial in Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater)
  • 09 Jul 2019 Helix Biopharma submits an IND application for a phase I/II trial in Pancreatic cancer (Combination therapy, Metastatic disease) to the US FDA
  • 29 Mar 2019 Pharmacodynamics data from a preclinical trial in Pancreatic cancer presented at the at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top